Dermata Therapeutics, Inc. (DRMA): Nasdaq/NYSE listing notice — Dermata receives Nasdaq extension to June 12, 2023 to regain $1 bid price compliance

Dermata Therapeutics, Inc.

Nasdaq granted extra 180 days (to June 12, 2023) to meet minimum $1.00 bid price per share.
Company previously received June 17, 2022 notice; initial 180-day grace period expired Dec 14, 2022.
May consider a reverse stock split to regain compliance if needed.
If compliance not regained by June 12, 2023, Nasdaq will start delisting proceedings.
Delisting risk could adversely affect liquidity, financing ability, and stock price.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dermata Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 15, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro

View on SEC.gov

Browse all listing & compliance notices →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-016569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.